HRTX
Heron Therapeutics, Inc.
There isn't enough reported data to score HRTX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HRTX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HRTX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HRTX PE Valuation
HRTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HRTX Forward outlook
There aren't enough analyst estimates for HRTX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.11 | -$0.02 |
| Q2 2026 | -$0.18 | -$0.16 |
| Q1 2026 | -$0.17 | -$0.11 |
| Q4 2025 | -$0.12 | -$0.03 |
| Q3 2025 | -$0.09 | +$0.09 |
| Q2 2025 | -$0.02 | +$0.30 |
| Q1 2025 | -$0.06 | +$0.55 |
| Q4 2024 | -$0.09 | +$0.77 |
HRTX is still losing money, but far less than before: $0.11 per share over the past year, against $2.52 at its worst in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HRTX on earnings quality, reporting a profit while its opponent remains loss making.
HRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.3M | -7.8% |
| Q2 2026 | $37.7M | +1.3% |
| Q1 2026 | $34.7M | -11% |
| Q4 2025 | $40.6M | -0.5% |
| Q3 2025 | $38.2M | +16% |
| Q2 2025 | $37.2M | +3.3% |
| Q1 2025 | $38.9M | +12% |
| Q4 2024 | $40.8M | +19% |
HRTX's revenue is shrinking: $35M last quarter, down 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.7% | +6 points |
| Q2 2026 | -5.4% | -1 points |
| Q1 2026 | -14% | -22 points |
| Q4 2025 | 0.1% | -10 points |
| Q3 2025 | -11% | +2.9 points |
| Q2 2025 | -4.4% | +14 points |
| Q1 2025 | 8.1% | +22 points |
| Q4 2024 | 10% | +40 points |
HRTX's operating margin was −4.7% last quarter, up 6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HRTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HRTX on profitability, with a higher operating margin.
HRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$896K | -167% |
| Q2 2026 | -$2.4M | +$8.7M |
| Q1 2026 | -$1.9M | +$7M |
| Q4 2025 | -$9.2M | +$3.2M |
| Q3 2025 | $1.3M | -55% |
| Q4 2024 | -$12.4M | -663% |
| Q3 2024 | $2.9M | +$12.9M |
| Q4 2023 | $2.2M | +$40.2M |
HRTX has burned cash in almost every quarter: −$14M over the past year, against −$31M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HRTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
HRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +584K shares |
| 1 year | +12% | +20.6M shares |
| 3 years | +32% | +45.9M shares |
| 5 years | +94% | +92.5M shares |
| Available history | +133% | +109M shares |
HRTX has 191M diluted shares, up 12% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HRTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HRTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | 37.5x | High |
HRTX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 18.9 | Oversold |
HRTX's weekly RSI is 38 (neutral) and its Stochastic is 19 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HRTX PE vs Healthcare Sector
HRTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 0% above |
| 20 week MA | $0.37 | 11% below |
| 50 week MA | $0.76 | 57% below |
| 100 week MA | $1.24 | 73% below |
| 200 week MA | $1.64 | 80% below |
HRTX is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HRTX on trend strength, trading above more of its moving averages.
HRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.1 | $20.7 | -14% |
| 2021 | $20.7 | $10.2 | -51% |
| 2022 | $10.2 | $2.57 | -75% |
| 2023 | $2.57 | $1.70 | -34% |
| 2024 | $1.70 | $1.55 | -8.8% |
| 2025 | $1.55 | $1.28 | -17% |
| 2026 YTD | $1.28 | $0.33 | -74% |
HRTX has finished every year since 2020 lower, and it's down 74% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HRTX on returns for 2026, with the stronger performance.